AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00039130
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
Trial: NCT00039130
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/sq m PO or IV Days 1-5 courses II-VII
Trial: NCT00039130
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
Trial: NCT00039130
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
Trial: NCT00039130
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/sq m PO/day Days 1-7 course I
Trial: NCT00039130
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg IV push Day 1 courses II-VII
Trial: NCT00039130
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/day PO Days 1-14, course I
Trial: NCT01018966
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
Trial: NCT00704639
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
Trial: NCT00704639
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly intravenous carboplatin (AUC 2) for the duration of the RT
Trial: NCT00908713
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
Trial: NCT03288129
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: film-coated tablets
Trial: NCT01950741
Drug: aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
Trial: NCT01866930
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01866930
Drug: Ribasphere (RBV)
RxNorm normalized name: Ribasphere
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02521870
Drug: SD-101(1)
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 administered intratumorally at escalating doses (up to 11 doses).
Trial: NCT02521870
Drug: SD-101(2)
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
Trial: NCT03471130
Drug: MT-8554 Low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, 7 days
Trial: NCT03471130
Drug: MT-8554 High dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 7 days
Trial: NCT02983344
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block using ropivacaine
Trial: NCT02854631
Drug: Selonsertib
RxNorm normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg tablet administered orally once daily
Trial: NCT01740947
Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
RxNorm normalized name: AMPHOTERICIN B CHOLESTERYL SULFATE
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
Trial: NCT04662125
Drug: oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
Trial: NCT00958750
Drug: minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the investigators compared two different formulations and concentrations of minoxidil in this study
Trial: NCT00268593
Drug: PI-88
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
Trial: NCT00268593
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
Trial: NCT00268593
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg twice a day orally
Trial: NCT00232024
Drug: Tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000208
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00580190
Drug: alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet, 0.5 mg, single dose, only on Day 7 of the study
Trial: NCT00580190
Drug: PF-00572778
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 500 mg, single dose, only on Day 7 of the study
Trial: NCT00004915
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02129400
Drug: Xenon pro Anaesthesia 100 % (V/V)
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenon-gas inhalation of indicated concentrations during indicated time
Trial: NCT05742100
Drug: Darvadstrocel
RxNorm normalized name: darvadstrocel
DrugBank: Darvadstrocel (DB16581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
Trial: NCT03384212
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03384212
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03384212
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03384212
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04554979
Drug: Hydroxychloroquine Pill
RxNorm normalized name: hydroxychloroquine Pill
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
Trial: NCT02091492
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
Trial: NCT02176499
Drug: Telmisartan, low dose
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02176499
Drug: Telmisartan, high dose
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01206660
Drug: Desoximetasone Spray 0.25%
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
Trial: NCT02537197
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular opioid antagonist dosing of disordered gamblers
Trial: NCT02708160
Drug: Fluoride Free toothpaste
RxNorm normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Trial: NCT00671697
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00671697
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01308060
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
Trial: NCT04419259
Drug: AMG 334
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Trial: NCT01799083
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
Trial: NCT01456468
Drug: Oral all-trans retinoic acid (ATRA)
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process.
Trial: NCT00748501
Drug: SB-509
RxNorm normalized name: SB-509
DrugBank: SB-509 (DB05579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
Trial: NCT01473836
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
Trial: NCT01473836
Drug: Ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
Trial: NCT00413452
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg once weekly
Trial: NCT00056524
Drug: AVP-923
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02550106
Drug: OMALIZUMAB
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sub cutaneous injections of 300 mg every 4 weeks until Week 8.
Trial: NCT04334863
Drug: WP1066
RxNorm normalized name: WP1066
DrugBank: WP-1066 (DB12679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Trial: NCT03018925
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
Trial: NCT00766337
Drug: Sirolimus in combination with ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Trial: NCT00766337
Drug: Sirolimus in combination with ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Trial: NCT00766337
Drug: Placebo in combination with ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Trial: NCT04055012
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg tabs of Metformin Extended Release
Trial: NCT03500094
Drug: Migalastat HCl 150 mg
RxNorm normalized name: Galafold 123 MG (as migalastat HCl 150 MG) Oral Capsule
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: migalastat HCl 150 mg capsule
Trial: NCT01196715
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aranesp 500 mcg vials once every 2 weeks.
Trial: NCT01196715
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mcg vials twice a week, 3-4 days apart
Trial: NCT03736616
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03736616
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03736616
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03736616
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03736616
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03736616
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03736616
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bruton's Tyrosine Kinase Inhibitor
Trial: NCT02161731
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02161731
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01158300
Drug: VEGF inhibitor PTC299
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: PTC299 (DB05173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
Trial: NCT03775655
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10μg dexmedetomidine will be added to the injectate to be injected intrathecally
Trial: NCT00059982
Drug: perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01432080
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
Trial: NCT01432080
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg PO qhs for 3 months
Trial: NCT01432080
Drug: Symbicort
RxNorm normalized name: Symbicort
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
Trial: NCT01192854
Drug: Clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine flexible dosages of 30 mg/day
Trial: NCT01192854
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir flexible dosages of 10 mg/day
Trial: NCT01013987
Drug: maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc: one 150 mg pill twice daily
Trial: NCT01013987
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir : one 400 mg pill twice daily
Trial: NCT01013987
Drug: Darunavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * darunavir : two 300 mg pills twice daily with meal~* ritonavir: one 100 mg pill twice daily with meal
Trial: NCT00571935
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04405102
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
Trial: NCT02092935
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02280954
Drug: Indocyanine Green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04378283
Drug: LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study is designed to evaluate topical anesthetics
Trial: NCT00190593
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04415476
Drug: Assigned Interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
Trial: NCT01393704
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Trial: NCT04325581
Drug: Liraglutide 6 MG/ML
RxNorm normalized name: liraglutide 6 MG/ML
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily